Results 1 to 10 of about 21,448 (153)

Reversible aripiprazole-induced tardive dyskinesia: a case series from Saudi Arabia and literature review [PDF]

open access: yesFrontiers in Psychiatry
Tardive dyskinesia (TD) is a slow-onset, hyperkinetic movement disorder involving repetitive involuntary movements. It is classified as a medication-induced movement disorder that occurs in association with the use of dopamine-blocking agents–most ...
Sultan M. Alshahrani   +5 more
doaj   +2 more sources

Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports [PDF]

open access: yesMental Health Clinician, 2021
Aripiprazole, an atypical antipsychotic, is a metabolic substrate for cytochrome P450 (CYP)3A4 and 2D6. Terbinafine, an antifungal agent used for onychomycosis, is a CYP2D6 inhibitor and could theoretically reduce the metabolism of aripiprazole. However,
Ian R. McGrane, PharmD   +2 more
doaj   +1 more source

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia

open access: yesBMC Psychiatry, 2023
Background Distinct oral atypical antipsychotics have different effects on autonomic nervous system (ANS) activity. Among them, oral aripiprazole has been linked to dysfunction of the ANS in schizophrenia.
Saki Hattori   +16 more
doaj   +1 more source

A Case of Hypersexuality in a Patient Receiving Aripiprazole for Schizophrenia

open access: yesCase Reports in Psychiatry, 2021
Aripiprazole is an antipsychotic with partial agonist activity at the dopamine D2 receptor which may lead to compulsive behaviors including hypersexuality.
Lakshmi Priya, Bini Moorthy
doaj   +1 more source

Aripiprazole disrupts cellular synchrony in the suprachiasmatic nucleus and enhances entrainment to environmental light–dark cycles in mice

open access: yesFrontiers in Neuroscience, 2023
Many patients with psychiatric conditions, such as bipolar disorder and major depressive disorder, frequently experience disruptions in their sleep–wake cycles.
Ruoshi Li   +10 more
doaj   +1 more source

Aripiprazole

open access: yesCNS Drugs, 2002
Aripiprazole is a quinolinone derivative and the first of a new class of atypical antipsychotics. The drug has partial agonist activity at dopamine D(2) and serotonin 5-HT(1A) receptors, and is also an antagonist at 5-HT(2A) receptors. In patients with acute relapse of schizophrenia or schizoaffective disorder, aripiprazole 15 to 30 mg/day was at least
Jane K, McGavin, Karen L, Goa
openaire   +4 more sources

Potentiation of the Antidepressant-Like Effect of Fluoxetine by Aripiprazole in the Mouse Tail Suspension Test

open access: yesJournal of Pharmacological Sciences, 2008
We examined the effect of the novel atypical antipsychotic drug aripiprazole alone or in combination with the selective serotonin reuptake inhibitor fluoxetine in the mouse tail suspension test.
Junzo Kamei   +5 more
doaj   +1 more source

Is aripiprazole similar to quetiapine for treatment of bipolar depression? Results from meta-analysis of Chinese data

open access: yesFrontiers in Psychiatry, 2022
ObjectiveTo study the similarities and differences in the clinical efficacy of aripiprazole and quetiapine in Chinese patients with bipolar depression through meta-analysis.
Hejian Tao   +6 more
doaj   +1 more source

Aripiprazole-induced transient myopia: A rare entity

open access: yesIndian Journal of Ophthalmology, 2018
Aripiprazole is a new drug for the treatment of adults with schizophrenia. Ocular side effects of aripiprazole are very rare. Review of literature revealed few cases of aripiprazole-induced myopia.
K V Praveen Kumar   +2 more
doaj   +1 more source

Relationship between subjective well-being and aripiprazole: an [11C]raclopride PET study

open access: yesScientific Reports, 2022
The dopamine blockade by antipsychotics trigger subjective dysphoria. Compared with D2 antagonists, aripiprazole, a D2 partial agonist, was expected to produce a different experience.
Seoyoung Kim   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy